"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC

被引：0
|
作者：
Zheng, Mei-Mei [1 ,2 ]
Wu, Yi-Long [1 ]
机构：
[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 06 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
[2] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 08期
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; GEFITINIB;
D O I：
10.1016/j.jtho.2024.04.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1146 / 1150
页数：5
相关论文
共 50 条
  • [41] Clinical-Pathological and Survival Analysis of Patients with Advanced NSCLC and EGFR Mutation Treated With a Drug Therapy Anti-T790M
    Corral, Jesus
    Cervera, Antonio
    Maiquez, Pilar
    Alonso, Miriam
    Dolores Mediano, Maria
    Jose Flor, Maria
    Jimenez, Lucia
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S411
  • [42] Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
    Mack, Philip C.
    Miao, Jieling
    Redman, Mary W.
    Moon, James
    Goldberg, Sarah B.
    Herbst, Roy S.
    Melnick, Mary Ann
    Walther, Zenta
    Hirsch, Fred R.
    Politi, Katerina
    Kelly, Karen
    Gandara, David R.
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3752 - 3760
  • [43] Thyroid Related Adverse Events Predict Survival in NSCLC Patients Receiving Anti-PD-1/ PD-L1 Therapy
    Ahmed, Y.
    Lee, J.
    Calvert, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S930 - S930
  • [44] Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
    Montagut, C.
    Alonso, V.
    Escudero, P.
    Fernandez-Martos, C.
    Salud Salvia, A.
    Mendez, M.
    Gallego Plazas, J.
    Rodriguez, J. R.
    Martin-Richard, M.
    Fernandez-Plana, J.
    Aparicio, J.
    Feliu Batlle, J.
    Garcia de Albeniz, X.
    Rojo, F.
    Fernandez, V.
    Claes, B.
    Maertens, G. G.
    Sablon, E.
    Jacobs, B. A. W.
    Maurel, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
    Mok, Tony
    Wu, Yi-Long
    Lee, Jin Soo
    Yu, Chong-Jen
    Sriuranpong, Virote
    Sandoval-Tan, Jennifer
    Ladrera, Guia
    Thongprasert, Sumitra
    Srimuninnimit, Vichien
    Liao, Meilin
    Zhu, Yunzhong
    Zhou, Caicun
    Fuerte, Fatima
    Margono, Benjamin
    Wen, Wei
    Tsai, Julie
    Truman, Matt
    Klughammer, Barbara
    Shames, David S.
    Wu, Lin
    CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3196 - 3203
  • [46] Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.
    Weinberg, Benjamin Adam
    Rakez, Manel
    Chibaudel, Benoist
    Maughan, Tim
    Adams, Richard
    Zalcberg, John Raymond
    Grothey, Axel
    Yoshino, Takayuki
    Shi, Qian
    De Gramont, Aimery
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [47] Postoperative Radiotherapy can Improve the Disease-Free Survival of EGFR Wild Type Patients with pN2 NSCLC after Complete Resection and Adjuvant Chemotherapy
    Liu, Y.
    Yang, X.
    Men, Y.
    Sun, S.
    Yuan, M.
    Bao, Y.
    Ma, Z.
    Zhai, Y. R.
    Wang, J.
    Deng, L.
    Wang, W.
    Bi, N.
    Wang, L.
    Hui, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E380 - E380
  • [48] The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st-or 2nd-line chemotherapy
    Izawa, N.
    Kudo, T.
    Yuki, S.
    Nakamura, M.
    Manaka, D.
    Kumekawa, Y.
    Mine, T.
    Okuno, T.
    Oda, H.
    Sagawa, T.
    Kawai, T.
    Shingai, T.
    Kotaka, M.
    Kobayashi, K.
    Kagawa, Y.
    Satake, H.
    Takeuchi, M.
    Ichikawa, W.
    Fujii, M.
    Sunakawa, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S430 - S430
  • [49] PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis
    Shuangjie Wu
    Yu Gan
    Xinhai Wang
    Jun Liu
    Mengjun Li
    Yifan Tang
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 891 - 900
  • [50] THE EFFECT OF ANTI-PD-1 THERAPY ON MEDIAN OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOBLASTOMA MULTIFORME PATIENTS WITH CERTAIN TUMOR MARKERS
    Paracha, Awais
    Campian, Jian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A128 - A128
12345